Histogen Inc.
DelistedCIK 1383701fmd_01DT6EBRZ4ZPTAY3FW917WG84FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2023, 52 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 1 | 35 | 34 | 22 | 2 | 1 | 4 |
| Realized investment gains (losses) | 0 | – | – | – | – | – | – | – | – | – |
| Research and development | 7 | 15 | 16 | 20 | 43 | 41 | 4 | 6 | 8 | 5 |
| Total operating expenses | 12 | 22 | 24 | 31 | 53 | 52 | 15 | 21 | 16 | 14 |
| Operating income | – | (22) | (24) | (30) | (18) | (18) | (3) | (19) | (15) | (11) |
| Interest expense | 0 | 0 | 0 | 0 | 1 | 1 | 0 | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 1 | – | – | – | – | – |
| Other non-operating income (expense) | (4) | (0) | (0) | 0 | 0 | 0 | 1 | 0 | 0 | – |
| Income tax expense | – | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Net income | (16) | (22) | (24) | (30) | (17) | (18) | (3) | (19) | (15) | (11) |
| Net income to common shareholders | (5) | (22) | (24) | – | – | – | (3) | (19) | (15) | (11) |